{
    "clinical_study": {
        "@rank": "164759", 
        "brief_summary": {
            "textblock": "The purpose of this study is collect and evaluate the clinical experience reached in Italy\n      on the use of bendamustine alone or combined with rituximab as treatment of patients with\n      relapsed or refractory chronic lymphoproliferative disorders."
        }, 
        "brief_title": "Efficacy and Safety Study of Bendamustine With or Without Rituximab in Chronic Lymphoproliferative Disorders", 
        "completion_date": {
            "#text": "January 2011", 
            "@type": "Actual"
        }, 
        "condition": "Chronic Lymphocytic Leukaemia", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Lymphocytic, Chronic, B-Cell", 
                "Leukemia, Lymphoid", 
                "Lymphoproliferative Disorders"
            ]
        }, 
        "detailed_description": {
            "textblock": "All patients who meet the criteria for inclusion will be included in the study. A specific\n      database will be created to collect the following information: personal data, medical\n      history, histology related to the underlying disease, comorbidities, laboratory data,\n      initial staging, data on the dosage and the number of cycles administered, the recorded\n      toxicity data, the clinical response and the main events (relapse, progression, death, and\n      cause of death). These data will then be retrospectively examined in order to obtain\n      information about the life-saving treatment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  patients with relapsed or refractory chronic lymphoproliferative disorders\n\n          -  salvage treatment with Bendamustine +/- Rituximab\n\n          -  age \u2265 18 years\n\n        Exclusion Criteria:\n\n          -  previous treatment with Bendamustine"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "All patients with relapsed or refractory chronic lymphoproliferative disorders treated\n        with Bendamustine +/- Rituximab"
            }
        }, 
        "enrollment": {
            "#text": "109", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01832597", 
            "org_study_id": "RetroBENDA"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Bendamustine", 
                "Rituximab"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 12, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Cosenza", 
                        "country": "Italy", 
                        "state": "CZ", 
                        "zip": "87100"
                    }, 
                    "name": "UO di Ematologia, S.O. Annunziata"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Modena", 
                        "country": "Italy", 
                        "state": "MO", 
                        "zip": "41124"
                    }, 
                    "name": "Dipartimento di Oncologia, Ematologia e Patologie dell'Apparato Respiratorio, Universita` di Modena e Reggio Emilia"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Palermo", 
                        "country": "Italy", 
                        "state": "PA", 
                        "zip": "90127"
                    }, 
                    "name": "UO di Ematologia, AOUP Paolo Giaccone,"
                }
            }
        ], 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_groups": "1", 
        "official_title": "A Retrospective Multicenter Trial on Efficacy and Toxicity of Bendamustine Alone or Associated With Rituximab, As Salvage Therapy in Patients With Chronic Lymphoproliferative Disorders", 
        "overall_official": [
            {
                "affiliation": "Gruppi Italiano Studi Linfomi", 
                "last_name": "Stefano Luminari, MD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Gruppo Italiano Studio Linfomi", 
                "last_name": "Emilio Iannitto, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Italy: The Italian Medicines Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2010", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Evaluate the activity of Bendamustine +/- Rituximab in term of ORR", 
            "measure": "Overall Response Rate (ORR)", 
            "safety_issue": "No", 
            "time_frame": "At least 2 months after completion of therapy"
        }, 
        "reference": [
            {
                "PMID": "6668489", 
                "citation": "Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol. 1983 Nov;1(11):710-9."
            }, 
            {
                "PMID": "18711176", 
                "citation": "Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables. J Clin Oncol. 2008 Aug 20;26(24):3913-5. doi: 10.1200/JCO.2008.16.1000."
            }, 
            {
                "PMID": "16219572", 
                "citation": "Bergmann MA, Goebeler ME, Herold M, Emmerich B, Wilhelm M, Ruelfs C, Boening L, Hallek MJ; German CLL Study Group. Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group. Haematologica. 2005 Oct;90(10):1357-64."
            }, 
            {
                "PMID": "19224851", 
                "citation": "Cheson BD, Rummel MJ. Bendamustine: rebirth of an old drug. J Clin Oncol. 2009 Mar 20;27(9):1492-501. doi: 10.1200/JCO.2008.18.7252. Epub 2009 Feb 17. Review. Erratum in: J Clin Oncol. 2009 Jun 10;27(17):2892."
            }, 
            {
                "PMID": "20223726", 
                "citation": "Cheson BD, Wendtner CM, Pieper A, Dreyling M, Friedberg J, Hoelzer D, Moreau P, Gribben J, Knop S, Montillo M, Rummel M. Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel. Clin Lymphoma Myeloma Leuk. 2010 Feb;10(1):21-7. doi: 10.3816/CLML.2010.n.002. Review."
            }, 
            {
                "PMID": "18334676", 
                "citation": "Ferrajoli A, Lee BN, Schlette EJ, O'Brien SM, Gao H, Wen S, Wierda WG, Estrov Z, Faderl SH, Cohen EN, Li C, Reuben JM, Keating MJ. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood. 2008 Mar 11; [Epub ahead of print]"
            }, 
            {
                "PMID": "18451308", 
                "citation": "Oskolkova OV, Afonyushkin T, Leitner A, von Schlieffen E, Gargalovic PS, Lusis AJ, Binder BR, Bochkov VN. ATF4-dependent transcription is a key mechanism in VEGF up-regulation by oxidized phospholipids: critical role of oxidized sn-2 residues in activation of unfolded protein response. Blood. 2008 Jul 15;112(2):330-9. doi: 10.1182/blood-2007-09-112870. Epub 2008 May 1."
            }, 
            {
                "PMID": "20033051", 
                "citation": "Foon KA, Hallek MJ. Changing paradigms in the treatment of chronic lymphocytic leukemia. Leukemia. 2010 Mar;24(3):500-11. doi: 10.1038/leu.2009.266. Epub 2009 Dec 24. Review."
            }, 
            {
                "PMID": "18642397", 
                "citation": "Forconi F, Fabbri A, Lenoci M, Sozzi E, Gozzetti A, Tassi M, Raspadori D, Lauria F. Low-dose oral fludarabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic Leukaemia. Hematol Oncol. 2008 Dec;26(4):247-51. doi: 10.1002/hon.868."
            }, 
            {
                "PMID": "19440214", 
                "citation": "Giannopoulos K, Dmoszynska A, Kowal M, Wasik-Szczepanek E, Bojarska-Junak A, Rolinski J, D\u00f6hner H, Stilgenbauer S, Bullinger L. Thalidomide exerts distinct molecular antileukemic effects and combined thalidomide/fludarabine therapy is clinically effective in high-risk chronic lymphocytic leukemia. Leukemia. 2009 Oct;23(10):1771-8. doi: 10.1038/leu.2009.98. Epub 2009 May 14."
            }, 
            {
                "PMID": "19850738", 
                "citation": "Gribben JG. How I treat CLL up front. Blood. 2010 Jan 14;115(2):187-97. doi: 10.1182/blood-2009-08-207126. Epub 2009 Oct 22. Review."
            }, 
            {
                "PMID": "11529853", 
                "citation": "Hallek M, Schmitt B, Wilhelm M, Busch R, Kr\u00f6ber A, Fostitsch HP, Sezer O, Herold M, Knauf W, Wendtner CM, Kuse R, Freund M, Franke A, Schriever F, Nerl C, D\u00f6hner H, Thiel E, Hiddemann W, Brittinger G, Emmerich B; German Chronic Lymphocytic Leukaemia Study Group. Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group. Br J Haematol. 2001 Aug;114(2):342-8."
            }, 
            {
                "PMID": "18216293", 
                "citation": "Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, D\u00f6hner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ; International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008 Jun 15;111(12):5446-56. Epub 2008 Jan 23. Erratum in: Blood. 2008 Dec 15;112(13):5259."
            }, 
            {
                "PMID": "19652068", 
                "citation": "Knauf WU, Lissichkov T, Aldaoud A, Liberati A, Loscertales J, Herbrecht R, Juliusson G, Postner G, Gercheva L, Goranov S, Becker M, Fricke HJ, Huguet F, Del Giudice I, Klein P, Tremmel L, Merkle K, Montillo M. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol. 2009 Sep 10;27(26):4378-84. Epub 2009 Aug 3."
            }, 
            {
                "PMID": "16520464", 
                "citation": "Lamanna N, Kalaycio M, Maslak P, Jurcic JG, Heaney M, Brentjens R, Zelenetz AD, Horgan D, Gencarelli A, Panageas KS, Scheinberg DA, Weiss MA. Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol. 2006 Apr 1;24(10):1575-81. Epub 2006 Mar 6."
            }, 
            {
                "PMID": "18172283", 
                "citation": "Leoni LM, Bailey B, Reifert J, Bendall HH, Zeller RW, Corbeil J, Elliott G, Niemeyer CC. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res. 2008 Jan 1;14(1):309-17."
            }, 
            {
                "PMID": "19826119", 
                "citation": "Lin TS, Ruppert AS, Johnson AJ, Fischer B, Heerema NA, Andritsos LA, Blum KA, Flynn JM, Jones JA, Hu W, Moran ME, Mitchell SM, Smith LL, Wagner AJ, Raymond CA, Schaaf LJ, Phelps MA, Villalona-Calero MA, Grever MR, Byrd JC. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol. 2009 Dec 10;27(35):6012-8. doi: 10.1200/JCO.2009.22.6944. Epub 2009 Oct 13."
            }, 
            {
                "PMID": "16292542", 
                "citation": "Lissitchkov T, Arnaudov G, Peytchev D, Merkle Kh. Phase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy. J Cancer Res Clin Oncol. 2006 Feb;132(2):99-104. Epub 2005 Nov 15."
            }, 
            {
                "PMID": "20194898", 
                "citation": "M\u00f6ssner E, Br\u00fcnker P, Moser S, P\u00fcntener U, Schmidt C, Herter S, Grau R, Gerdes C, Nopora A, van Puijenbroek E, Ferrara C, Sondermann P, J\u00e4ger C, Strein P, Fertig G, Friess T, Sch\u00fcll C, Bauer S, Dal Porto J, Del Nagro C, Dabbagh K, Dyer MJ, Poppema S, Klein C, Uma\u00f1a P. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood. 2010 Jun 3;115(22):4393-402. doi: 10.1182/blood-2009-06-225979. Epub 2010 Mar 1."
            }, 
            {
                "PMID": "19536902", 
                "citation": "Motta M, Wierda WG, Ferrajoli A. Chronic lymphocytic leukemia: treatment options for patients with refractory disease. Cancer. 2009 Sep 1;115(17):3830-41. doi: 10.1002/cncr.24479. Review."
            }, 
            {
                "PMID": "11230486", 
                "citation": "O'Brien SM, Kantarjian HM, Cortes J, Beran M, Koller CA, Giles FJ, Lerner S, Keating M. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol. 2001 Mar 1;19(5):1414-20."
            }, 
            {
                "PMID": "20194844", 
                "citation": "Robak T, Dmoszynska A, Solal-C\u00e9ligny P, Warzocha K, Loscertales J, Catalano J, Afanasiev BV, Larratt L, Geisler CH, Montillo M, Zyuzgin I, Ganly PS, Dartigeas C, Rosta A, Maurer J, Mendila M, Saville MW, Valente N, Wenger MK, Moiseev SI. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol. 2010 Apr 1;28(10):1756-65. doi: 10.1200/JCO.2009.26.4556. Epub 2010 Mar 1."
            }, 
            {
                "PMID": "20376452", 
                "citation": "Tageja N, Nagi J. Bendamustine: something old, something new. Cancer Chemother Pharmacol. 2010 Aug;66(3):413-23. doi: 10.1007/s00280-010-1317-x. Epub 2010 Apr 8. Review."
            }, 
            {
                "PMID": "15767647", 
                "citation": "Wierda W, O'Brien S, Wen S, Faderl S, Garcia-Manero G, Thomas D, Do KA, Cortes J, Koller C, Beran M, Ferrajoli A, Giles F, Lerner S, Albitar M, Kantarjian H, Keating M. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol. 2005 Jun 20;23(18):4070-8. Epub 2005 Mar 14."
            }, 
            {
                "PMID": "20194866", 
                "citation": "Wierda WG, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, Robak T, Furman RR, Hillmen P, Trneny M, Dyer MJ, Padmanabhan S, Piotrowska M, Kozak T, Chan G, Davis R, Losic N, Wilms J, Russell CA, Osterborg A; Hx-CD20-406 Study Investigators. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2010 Apr 1;28(10):1749-55. doi: 10.1200/JCO.2009.25.3187. Epub 2010 Mar 1. Erratum in: J Clin Oncol. 2010 Aug 1;28(22):3670."
            }, 
            {
                "PMID": "19956173", 
                "citation": "Zenz T, Mertens D, K\u00fcppers R, D\u00f6hner H, Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer. 2010 Jan;10(1):37-50. doi: 10.1038/nrc2764. Epub 2009 Dec 3. Review."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01832597"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Evaluate the activity of Bendamustine +/- Rituximab in term of PFS and OS", 
                "measure": "Progression Free Survival (PFS) and Overall Survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "From the date of frist treatment cycle until the date of first documented progression or date of death for any cause,  whichever came first, assessed up to 150 months"
            }, 
            {
                "description": "Assess to efficacy of Bendamustine +/- Rituximab in term of grade III and IV  National Cancer Institute Common Toxicity Criteria (NCI CTC) adverse events", 
                "measure": "Number of Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "From the date of first tratment cycle until 6 months after the date of last treatment cycle"
            }
        ], 
        "source": "Gruppo Italiano Studio Linfomi", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gruppo Italiano Studio Linfomi", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2010", 
        "study_design": "Observational Model: Cohort, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "April 2013"
    }
}